RT Journal Article
SR Electronic
T1 Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.12.22269148
DO 10.1101/2022.01.12.22269148
A1 Mary-Ann Davies
A1 Reshma Kassanjee
A1 Petro Rosseau
A1 Erna Morden
A1 Leigh Johnson
A1 Wesley Solomon
A1 Nei-Yuan Hsiao
A1 Hannah Hussey
A1 Graeme Meintjes
A1 Masudah Paleker
A1 Theuns Jacobs
A1 Peter Raubenheimer
A1 Alexa Heekes
A1 Pierre Dane
A1 Jamy-Lee Bam
A1 Mariette Smith
A1 Wolfgang Preiser
A1 David Pienaar
A1 Marc Mendelson
A1 Jonathan Naude
A1 Neshaad Schrueder
A1 Ayanda Mnguni
A1 Sue Le Roux
A1 Katie Murie
A1 Hans Prozesky
A1 Hassan Mahomed
A1 Liezel Rossouw
A1 Sean Wasserman
A1 Deborah Maughan
A1 Linda Boloko
A1 Barry Smith
A1 Jantjie Taljaard
A1 Greg Symons
A1 Ntobeko Ntusi
A1 Arifa Parker
A1 Nicole Wolter
A1 Waasila Jassat
A1 Cheryl Cohen
A1 Richard Lessells
A1 Robert J Wilkinson
A1 Juanita Arendse
A1 Saadiq Kariem
A1 Melvin Moodley
A1 Krish Vallabhjee
A1 Milani Wolmarans
A1 Keith Cloete
A1 Andrew Boulle
A1 On behalf of the Western Cape and South African National Departments of Health in collaboration with the National Institute for Communicable Diseases in South Africa
YR 2022
UL http://medrxiv.org/content/early/2022/01/12/2022.01.12.22269148.abstract
AB Objectives We aimed to compare COVID-19 outcomes in the Omicron-driven fourth wave with prior waves in the Western Cape, the contribution of undiagnosed prior infection to differences in outcomes in a context of high seroprevalence due to prior infection, and whether protection against severe disease conferred by prior infection and/or vaccination was maintained.Methods In this cohort study, we included public sector patients aged ≥20 years with a laboratory confirmed COVID-19 diagnosis between 14 November-11 December 2021 (wave four) and equivalent prior wave periods. We compared the risk between waves of the following outcomes using Cox regression: death, severe hospitalization or death and any hospitalization or death (all ≤14 days after diagnosis) adjusted for age, sex, comorbidities, geography, vaccination and prior infection.Results We included 5,144 patients from wave four and 11,609 from prior waves. Risk of all outcomes was lower in wave four compared to the Delta-driven wave three (adjusted Hazard Ratio (aHR) [95% confidence interval (CI)] for death 0.27 [0.19; 0.38]. Risk reduction was lower when adjusting for vaccination and prior diagnosed infection (aHR:0.41, 95% CI: 0.29; 0.59) and reduced further when accounting for unascertained prior infections (aHR: 0.72). Vaccine protection was maintained in wave four (aHR for outcome of death: 0.24; 95% CI: 0.10; 0.58).Conclusions In the Omicron-driven wave, severe COVID-19 outcomes were reduced mostly due to protection conferred by prior infection and/or vaccination, but intrinsically reduced virulence may account for an approximately 25% reduced risk of severe hospitalization or death compared to Delta.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding for the Western Cape Provincial Health Data Centre from the Western Cape Department of Health, the US National Institutes for Health (R01 HD080465, U01 AI069924), the Bill and Melinda Gates Foundation (1164272, 119327), the United States Agency for International Development (72067418CA00023), the European Union (101045989), the Wellcome Trust (203135/Z/16/Z, 222574) and the Medical Research Council of South Africa. RJW receives support from the Francis Crick Institute which is funded by Wellcome (FC0010218), MRC (UK) (FC0010218) and Cancer Research UK (FC0010218). He also receives support from Wellcome (203135, 222574) and the Medical Research Council of South Africa.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committee, University of Cape Town Faculty of Health Sciences, South AfricaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.